Session: MON 327-337-Neuroendocrine Tumors
Poster Board MON-330
Goals This retrospective study was performed to evaluate if there is a metabolic impairment in NF-PNET.
Results: Thirty nine consecutive patients with histologically confirmed NF-NETs were assessed, with a F/M ratio 14/25, mean (+/-SD) age of 60.7±12.8 y, 22 with previous pancreatic surgery and 17 prior to/without surgery. Mean tumor size was 2.8±2.3 cm. More than two thirds (66%) of this cohort had impaired glucose metabolism: 44% (17/39) had overt diabetes mellitus (DM) and 23% had impaired fasting glucose (IFG). Mean (on treatment, in several patients) fasting glucose level was 111±21mg/dl, HBA1c 6.9±2.1% and BMI 28.7± 6.3 kg/m2. The rate of DM in subjects operated for PNET and subjects who were not operated on was 45% and 35%, respectively and the corresponding rates for IFG was 24% and 23%, respectively. BMI was lower in the subgroup subjected to surgery (26.1±2.4 vs. 32 ±8 kg/m2; p<0.02).
Conclusion: This is the first report presenting the surprising finding of a high prevalence of impairment in glucose metabolism in patients with NF-PNET. The high prevalence of diabetes/prediabetes cannot be attributed to age, obesity or surgery alone, though each could have a contributory role. If verified in larger series of patients, this observation should prompt re-examination of the term "non-functioning" in the context of PNET and/or raise the possibility of increased rate of "NF"-PNETs in type 2 diabetes/prediabetes.
Nothing to Disclose: EO, ES, YG, KMT, YS, AM, MB, IN, RG, ES, NS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters